KZKinga Zachar

Kinga Zachar

*This is an algorithmically generated author record based on publicly available information.

Kinga Zachar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Resistance Training and Healthy Aging: Effects on Sarcopenia, Cognitive Function and Quality of Life - A Narrative Review

    by Maksymilian Sito, Kinga Zachar, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Zuzanna Marczak, Monika Jarowicz, JęDrzej Czmyr

    Background. Population aging causes loss of muscle strength, mass and functional reserve, increasing the risk of sarcopenia, frailty, falls, disability and lower quality of life. Resistance training is a documented non-pharmacological strategy for preserving musculoskeletal function and may support cognition and well-being.Aim. To summarize evidence on resistance training in healthy aging, focusing on sarcopenia, cognition and quality of life.Material and methods. PubMed/MEDLINE sources were reviewed, prioritizing consensus documents, randomized trials, systematic reviews and meta-analyses.Results. Sarcopenia is defined mainly by low muscle strength; low muscle quantity or quality confirms diagnosis, and poor physical performance indicates severe disease. Progressive resistance training improves strength and function in older adults. In sarcopenia, meta-analyses show benefits for handgrip strength, gait speed and sit-to-stand performance, with variable effects on muscle mass and quality of life. Cognitive effects are promising but inconsistent, with possible benefits for global cognition and memory.Conclusions. Resistance training is a core healthy-aging intervention and first-line non-pharmacological strategy for sarcopenia. Strongest evidence concerns strength and physical function; cognitive and quality-of-life effects are relevant but less uniform. Safe use requires individualized progression, supervision, fall-risk reduction and nutrition or aerobic/balance exercise.

  • Open Access

    Meat Consumption and Cerebrovascular Disease An Updated Review of Stroke Risk and Mortality

    by JęDrzej Czmyr, Zuzanna Marczak, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Kinga Zachar, Monika Jarowicz

    Introduction and aim of the study Strokes are a leading cause of global mortality and disability. While diet is a key modifiable risk factor, the impact of specific proteins requires clarification. This review evaluates evidence on how unprocessed red meat, processed meat, white meat, and fish affect stroke risk to inform dietary guidelines. Materials and methods A literature search of PubMed, Embase, and the Cochrane Library focused on large-scale meta-analyses, prospective cohort studies, and established pathophysiology linking specific meat types with stroke outcomes. State of Knowledge Evidence shows a distinct stroke risk gradient by meat type. Processed meat is a potent risk factor; a 50g/day intake raises stroke risk by 11–17%, driven by sodium and nitrites inducing hypertension. Unprocessed red meat shows a modest association; a 100g/day increase is linked to an 11–13% higher ischemic stroke risk, likely mediated by heme iron and the gut metabolite TMAO. Conversely, white meat has a neutral or slightly protective effect. Fish offers robust protection; its consumption reduces stroke risk by 14%, attributed to marine n-3 polyunsaturated fatty acids. Conclusions Protein choices significantly influence stroke risk. Limiting processed and unprocessed red meats, and substituting them with fish or white meat, is an effective stroke prevention strategy. Further research should clarify the impact of preparation methods and specific stroke subtypes.

  • Open Access

    Effectiveness and safety of deprescribing interventions in older adults with polypharmacy: a review of clinical trials from 2017 to 2026

    by Aleksandra Dobracka, Hubert Tomasz Bojanowski, Natalia Gawron, Maksymilian Sito, JęDrzej Czmyr, Zuzanna Marczak, Monika Jarowicz, Łukasz Wójcik, Filip Jurkowski, Kinga Zahar

    Background. Population aging contributes to the rising prevalence of multimorbidity and polypharmacy, which increase the risk of adverse drug events and deterioration in quality of life among older adults. Deprescribing is a planned process of treatment optimization aimed at reducing unnecessary medication burden and improving patient well-being. Aim. The objective of this study is to summarize current scientific evidence on the clinical effectiveness and safety of deprescribing interventions in older adults based on a review of clinical trials published between 2017 and 2026. Material and methods. A review of English-language clinical trials published between 2017 and 2026 was conducted using the PubMed and Google Scholar databases, with the following search terms: “deprescribing,” “polypharmacy,” “inappropriate prescribing” and “potentially inappropriate.” Studies assessing the safety and clinical outcomes of deprescribing in individuals aged 65 years and older with polypharmacy were included. Results. Deprescribing appears to have a neutral effect on mortality and hospitalizations, supporting the safety of this intervention. Its impact on the incidence of falls in older adults remains inconclusive. At the same time, improvements in quality of life, functional status, and selected cognitive functions are observed, particularly following the reduction of central nervous system–acting medications and drugs with anticholinergic properties. Conclusions. Deprescribing is a safe treatment strategy that improves selected aspects of patient functioning. Rational medication selection, rather than the total number of medications, is of key importance. Future studies should incorporate extended follow-up periods to better assess long-term health outcomes.

  • Open Access

    Hyponatremia as a Prognostic Factor in Heart Failure: A Narrative Review

    by Natalia Gawron, Filip Jurkowski, Hubert Tomasz Bojanowski, JęDrzej Czmyr, Maksymilian Sito, Zuzanna Marczak, Aleksandra Dobracka, Kinga Zachar, Monika Jarowicz, Łukasz Wójcik

    Introduction and purpose: Hyponatremia is the most frequent electrolyte abnormality in heart failure (HF) and reflects neurohormonal activation, congestion, renal dysfunction, and treatment intensity. This narrative review assesses whether hyponatremia is only a marker of advanced HF or an independent prognostic factor, and summarizes its value for risk stratification.Brief description of the state of knowledge: Across acute and chronic HF cohorts, low serum sodium at admission is consistently associated with longer hospitalization, higher in-hospital mortality, greater post-discharge mortality, and more frequent rehospitalization. Prognostic relevance is also seen for persistent hyponatremia, discharge hyponatremia, hospital-acquired hyponatremia, and worsening sodium trajectories during admission. These associations are present in both reduced and preserved ejection fraction and become stronger when hyponatremia coexists with renal dysfunction, severe congestion, or elevated natriuretic peptides. Cohort studies suggest that sodium improvement during hospitalization is linked to better short-term outcomes, but randomized evidence shows that sodium correction alone does not lower mortality.Summary (conclusions): Hyponatremia should be considered a readily available, low-cost prognostic marker in HF rather than an isolated laboratory abnormality. Its value is greatest when interpreted together with congestion, kidney function, and natriuretic peptide burden. Persistent or hospital-acquired hyponatremia identifies particularly vulnerable patients who may benefit from closer monitoring, careful volume reassessment, and optimized guideline-directed therapy. Future studies should determine whether phenotype-guided correction strategies can improve hard clinical outcomes.

  • Open Access

    Sweat in Skin Homeostasis and Dermatological Disorders in Athletes: Structural, Functional, and Clinical Perspectives - A Narrative Review

    by Monika Jarowicz, Zuzanna Marczak, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Kinga Zachar, JęDrzej Czmyr

    Introduction and purpose. Sweat is essential for skin homeostasis. In physically active individuals, increased sweating supports protective skin functions but may also trigger dermatological conditions. This review summarizes current knowledge on sweat gland types, their functional diversity, and the role of sweat in skin homeostasis, dermatoses, and gland disorders. Material and method. A narrative review of the literature was conducted using PubMed and Google Scholar, including original articles and reviews on sweat gland physiology, sweat composition, and related dermatoses.Results. Secretions from eccrine, apocrine, and apoeccrine glands contain water, electrolytes, and bioactive molecules that contribute to epidermal barrier integrity and immune functions. In physically active individuals, increased sweating improves heat dissipation, enhances stratum corneum hydration, and facilitates the delivery of antimicrobial and immunomodulatory factors to the skin surface. However, prolonged moisture and friction may disrupt the skin barrier and promote microbial overgrowth, contributing to inflammatory, infectious, and exacerbate dermatoses. Sweat gland disorders, further illustrate the consequences of dysregulated sweating, leading to impaired thermoregulation, inflammation, discomfort, and reduced physical performance.Conclusions. Sweat has multifactorial effects on skin health, influenced by environmental and individual factors. Understanding sweat physiology and related disorders is essential for preventing and managing skin diseases.

  • Open Access

    Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects — A Narrative Review

    by Kinga Zachar, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Zuzanna Marczak, Monika Jarowicz, JęDrzej Czmyr

    Introduction and purpose: Depressive disorders, particularly major depressive disorder (MDD) and treatment-resistant depression (TRD), remain major causes of disability worldwide. Conventional treatments are limited by delayed onset, incomplete response, relapse, and adverse effects. This review summarizes current evidence on the efficacy, safety, and durability of psilocybin-assisted therapy in depressive disorders. Brief description of the state of knowledge: Evidence from randomized trials, open-label studies, follow-up analyses, and meta-analyses indicates that psilocybin-assisted therapy can produce rapid reductions in depressive symptoms, often within days, in carefully selected patients treated in controlled settings. Short-term benefits have been reported in both MDD and TRD, although findings in TRD are less consistent. In a head-to-head trial, psilocybin was not superior to escitalopram on the primary endpoint, while several secondary outcomes favored psilocybin. Follow-up studies suggest that benefits may persist for weeks to months, but longer-term evidence remains limited and heterogeneous. Under supervision, psilocybin was generally well tolerated, with mostly transient adverse effects, including anxiety, nausea, headache, dizziness, and brief cardiovascular activation. Summary: Psilocybin-assisted therapy appears to be a promising investigational approach for depressive disorders, with rapid onset and possible medium-term benefit in some patients. However, the evidence base remains limited by small samples, heterogeneous designs, restricted comparative data, and delivery in specialized settings. Larger and longer-term studies are needed to clarify comparative efficacy, durability, long-term safety, and feasibility in routine clinical practice.

  • Open Access

    Synergy of Protein Intake and Strength Exercise in Overcoming Anabolic Resistance in Sarcopenia Management

    by Łukasz Wójcik, JęDrzej Czmyr, Hubert Tomasz Bojanowski, Zuzanna Marczak, Maksymilian Sito, Filip Jurkowski, Natalia Gawron, Aleksandra Dobracka, Kinga Zachar, Monika Jarowicz

    Background. Sarcopenia is characterized by accelerated muscle loss, driven by chronic inflammation and anabolic resistance, which blunts mTORC1 pathway activation in aging skeletal muscle. Aim. This narrative review analyzes the efficacy and synergistic effects of targeted protein supplementation and resistance exercise in countering sarcopenia. Material and methods. A literature search of PubMed and Google Scholar was conducted to identify recent clinical guidelines and studies on protein supplementation, leucine thresholds, and mechanotransduction in older adults. Results. Overcoming anabolic resistance requires a high intracellular leucine threshold of 2.5–3.0 g per meal. Whey protein effectively provides this rapid spike. Furthermore, progressive resistance training independently upregulates mTORC1 via mechanotransduction. Combining these interventions with specific adjuvants like creatine robustly sustains an anabolic environment. Conclusions. Effective sarcopenia management requires shifting from passive treatments to active interventions combining mechanical loading with targeted nutritional triggers.

  • Open Access

    Effects of GLP-1 Receptor Agonists on Bone Metabolism and Fracture Risk in Type 2 Diabetes and Obesity: Mechanisms and Clinical Evidence — A Narrative Review

    by Hubert Bojanowski, Zuzanna Marczak, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Aleksandra Dobracka, Kinga Zachar, Monika Jarowicz, JęDrzej Czmyr

    Introduction and purpose: Type 2 diabetes (T2D) is associated with increased fragility fracture risk despite preserved or elevated bone mineral density (BMD) ("diabetic bone paradox"). As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in T2D and obesity, this narrative review synthesizes evidence on their effects on bone turnover, BMD and fracture outcomes, contrasting diabetic and non-diabetic populations. Brief description of the state of knowledge: Preclinical data suggest GLP-1 RAs may promote osteoblastogenesis and reduce marrow adipogenesis (e.g., via Wnt/$\beta$-catenin and OPG/RANKL signalling). Clinically, effects appear context-dependent and strongly influenced by weight loss. In T2D, most trials report neutral or small favourable changes in BMD and bone turnover markers. Some meta-analyses report a possible reduction in fractures (notably with longer liraglutide exposure), but fracture events were often secondary/safety endpoints and were not adjudicated, limiting certainty. Summary (conclusions): Overall, current evidence to date suggests no major skeletal safety signal for GLP-1 RAs in T2D, while definitive fracture-prevention effects remain unproven. In obesity, baseline risk assessment and monitoring of bone health should be considered in high-risk individuals, and future studies should prioritize adjudicated fracture endpoints and longer follow-up.

  • Open Access

    Iron Deficiency in Heart Failure: Pathophysiology, Diagnosis, and Therapeutic Strategies – A Narrative Review

    by Filip Jurkowski, Maksymilian Sito, Zuzanna Marczak, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Kinga Zachar, Monika Jarowicz, JęDrzej Czmyr

    Introduction and Purpose: Heart failure (HF) imposes a significant global burden. Iron deficiency (ID) constitutes a prevalent comorbidity affecting up to 50% of patients, independently worsening prognosis regardless of anemia status. This review analyzes the pathophysiology of ID, specifically impaired myocardial energetics, clarifies diagnostic criteria, and compares the efficacy of oral versus intravenous therapeutic strategies. A comprehensive literature search was conducted using PubMed, Scopus, and Embase (2015–2026). The review focuses on landmark randomized trials (AFFIRM-AHF, IRONMAN, HEART-FID), recent meta-analyses, and current international guidelines . State of knowledge: ID impairs mitochondrial oxidative phosphorylation and myocardial contractility. In HF, chronic inflammation may upregulate hepcidin, which induces the internalization and degradation of ferroportin, blocking intestinal iron absorption. Consequently, evidence from randomized trials suggests that oral iron supplementation has not demonstrated consistent clinical benefit in repleting iron stores or improving functional capacity in patients with heart failure. In contrast, intravenous iron formulations (ferric carboxymaltose, ferric derisomaltose) bypass these regulatory barriers. Evidence indicates that intravenous repletion significantly improves exercise capacity and quality of life, and reduces the risk of recurrent HF hospitalizations. Summary: Assessment of iron status using serum ferritin and transferrin saturation is a vital aspect of modern heart failure management. Due to physiological absorption barriers and systemic inflammation, oral iron supplementation has not demonstrated consistent clinical benefit in this population. Current evidence supports intravenous iron repletion as an effective, evidence-based strategy for improving symptoms and reducing the risk of hospitalizations, specifically in symptomatic patients with HFrEF or HFmrEF and concomitant iron deficiency.


  • Open Access

    Physical Activity in the Prevention and Treatment of Depression and Anxiety Disorders: A Narrative Literature Review

    by Zuzanna Marczak, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Bojanowski, Aleksandra Dobracka, Kinga Zachar, Monika Jarowicz, JęDrzej Czmyr

    Background. Depression and anxiety represent a massive global health burden. Because standard pharmacotherapy and psychotherapy often exhibit clinical limitations, there is a need for a multidisciplinary approach. In this context, physical activity serves as an effective complementary strategy. Aim. The aim of this study was to synthesize current literature regarding the impact of physical activity on the prevention and treatment of depression and anxiety disorders. Material and methods. A narrative literature review search of PubMed and Google Scholar was conducted to retrieve high-quality evidence, including meta-analyses, systematic reviews, and randomized controlled trials published between 2015 and 2026. Results. Evidence suggests that exercise interventions may produce symptom reductions comparable to those reported in some pharmacotherapy trials. The benefits follow a "some is better than none" principle, where even low volumes of exercise significantly reduce psychiatric symptoms. These protective and therapeutic effects are driven by a dual mechanism. Neurobiological adaptations, such as Brain-Derived Neurotrophic Factor (BDNF) upregulation and reduced inflammation, work alongside psychosocial improvements. Conclusions. Physical activity is a robust, evidence-based intervention. Therefore, clinicians should integrate the "Exercise as Medicine" framework into psychiatric care. Furthermore, future research should prioritize longitudinal designs and protocols to effectively overcome motivational barriers.